P
P.M. Poortmans
Researcher at Curie Institute
Publications - 51
Citations - 3300
P.M. Poortmans is an academic researcher from Curie Institute. The author has contributed to research in topics: Breast cancer & Radiation therapy. The author has an hindex of 12, co-authored 51 publications receiving 2717 citations.
Papers
More filters
Journal ArticleDOI
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Elżbieta Senkus,Stella Kyriakides,Frédérique Penault-Llorca,P.M. Poortmans,Alexander J. Thompson,Sophia Zackrisson,Fatima Cardoso +6 more
TL;DR: This work presents the results of a meta-analysis conducted at the 2016 European Oncology and Radiotherapy Guidelines Working Group (ESMO) workshop on breast cancer diagnosis and prognosis of women with atypical central giant cell granuloma (CGM) who have previously had surgery.
Journal ArticleDOI
O-113 Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the Randomized Boost Versus No Boost EORTC 22881–10882 Trial
H. Struikmans,H. Bartelink,Jean-Claude Horiot,P.M. Poortmans,W. Van den Bogaert,Alain Fourquet,Jos J. Jager,W.J. Hoogenraad,S. Bing Oei,C.C. Wárlám-Rodenhuis,Marianne Pierart,L. Collette +11 more
TL;DR: A boost dose of 16 Gy led to improved local control in all age groups, but no difference in survival, and the number of salvage mastectomies has been reduced by 41%.
Journal ArticleDOI
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
Sophie Gourgou-Bourgade,David Cameron,P.M. Poortmans,Bernard Asselain,D. Azria,Fatima Cardoso,Roger A'Hern,Judith M Bliss,Jan Bogaerts,Hervé Bonnefoi,Etienne Brain,Maria João Cardoso,Benoist Chibaudel,Robert E. Coleman,Tanja Cufer,L. Dal Lago,Florence Dalenc,E. de Azambuja,Marc Debled,Suzette Delaloge,Thomas Filleron,Joseph Gligorov,Maciej Gutowski,William Jacot,C. Kirkove,Gaëtan MacGrogan,Stefan Michiels,Stefan Michiels,I. Negreiros,Birgitte Vrou Offersen,F. Penault Llorca,Giancarlo Pruneri,Giancarlo Pruneri,Henri Roché,Nicola S. Russell,Fernando Schmitt,V. Servent,Beat Thürlimann,Michael Untch,J.A. van der Hage,G. van Tienhoven,Hans Wildiers,John Yarnold,F. Bonnetain,Simone Mathoulin-Pélissier,Carine Bellera,T. S. Dabakuyo-yonli +46 more
TL;DR: Recommendations for the definitions of TTE end points commonly used in RCTs for breast cancer are provided for non-metastatic and metastatic settings and should facilitate comparisons of trial results and improve the quality of trial design and reporting.
Journal ArticleDOI
The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial.
P.M. Poortmans,Laurence Collette,Harry Bartelink,H. Struikmans,W. Van den Bogaert,Alain Fourquet,Jos J. Jager,W.J. Hoogenraad,R.P. Muller,Jean-Bernard Dubois,M. Bolla,M. van der Hulst,C.C. Wárlám-Rodenhuis,Marianne Pierart,Jean-Claude Horiot +14 more
TL;DR: An increase of the dose with 16 Gy improved local control for patients after a complete lumpectomy only and the development of fibrosis was clearly dose dependent, which was significantly dependent on the boost dose.
Journal ArticleDOI
Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study
Cem Onal,Yexiong Li,Robert C. Miller,P.M. Poortmans,N. Constantinou,Damien C. Weber,Beste M. Atasoy,Sefik Igdem,Mahmut Ozsahin,Enis Ozyar +9 more
TL;DR: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.